About Satiogen
Satiogen is a company based in San Diego (United States) founded in 2007 by Andrew Young and Bronislava Gedulin was acquired by Mirum Pharmaceuticals in May 2022.. Satiogen has raised $700 thousand across 1 funding round from investors including Mirum Pharmaceuticals and Mesa Verde Venture Partners. Satiogen operates in a competitive market with competitors including Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics, Cellino and Adocia, among others.
- Headquarter San Diego, United States
- Founders Andrew Young, Bronislava Gedulin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$700 K (USD)
in 1 rounds
-
Latest Funding Round
$700 K (USD), Series A
Apr 15, 2008
-
Investors
Mirum Pharmaceuticals
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Mirum Pharmaceuticals
(May 23, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Satiogen
Satiogen has successfully raised a total of $700K through 1 strategic funding round. The most recent funding activity was a Series A round of $700 thousand completed in April 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $700,000
-
First Round
First Round
(15 Apr 2008)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2008 | Amount | Series A - Satiogen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Satiogen
Satiogen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Mirum Pharmaceuticals and Mesa Verde Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Small molecule therapeutics are developed for rare diseases treatment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Satiogen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Satiogen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Satiogen Comparisons
Competitors of Satiogen
Satiogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics, Cellino and Adocia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Pendulum is focused on developing advanced probiotic solutions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Satiogen
When was Satiogen founded?
Satiogen was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Where is Satiogen located?
Satiogen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Satiogen?
Dan Wood is the current CEO of Satiogen.
Is Satiogen a funded company?
Satiogen is a funded company, having raised a total of $700K across 1 funding round to date. The company's 1st funding round was a Series A of $700K, raised on Apr 15, 2008.
What does Satiogen do?
Satiogen Pharmaceuticals has discovered a metabolic mechanism of action termed the bile acid brake that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. Preclinical experiments testing several drugable concepts have demonstrated metabolic effects comparable to marketed drugs, and a clinical study has extended these findings to humans. Preclinical experiments are also underway with a non-surgical device designed to replicate the benefits of gastric bypass surgery.
Who are the top competitors of Satiogen?
Satiogen's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Who are Satiogen's investors?
Satiogen has 2 investors. Key investors include Mirum Pharmaceuticals, and Mesa Verde Venture Partners.